Abattis Bioceuticals Corp. announced the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the company hopes to launch Comfort through the company’s wholly-owned subsidiary, Vergence Naturals Ltd.